Tresiba (Novo Nordisk)
Welcome to the PulseAid listing for the Tresiba drug offered from Novo Nordisk. This Insulin [Chemical/Ingredient],Insulin Analog [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Novo Nordisk |
| NON-PROPRIETARY NAME: | insulin degludec injection |
| SUBSTANCE NAME: | INSULIN DEGLUDEC |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Insulin [Chemical/Ingredient],Insulin Analog [EPC] |
| ROUTE: | SUBCUTANEOUS |
| DOSAGE FORM: | INJECTION, SOLUTION |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2015-09-25 |
| END MARKETING DATE: | 0000-00-00 |
Tresiba HUMAN PRESCRIPTION DRUG Details:
| Item Description | Tresiba from Novo Nordisk |
| LABELER NAME: | Novo Nordisk |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 200(U/mL) |
| START MARKETING DATE: | 2015-09-25 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0169-2550_650a6e03-484a-4ae9-ab25-730eb679a102 |
| PRODUCT NDC: | 0169-2550 |
| APPLICATION NUMBER: | NDA203314 |
Other INSULIN DEGLUDEC Pharmaceutical Manufacturers / Labelers:
